Free Trial

Axsome Therapeutics (AXSM) Competitors

Axsome Therapeutics logo
$127.94 +2.94 (+2.35%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$130.00 +2.06 (+1.61%)
As of 10/17/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AXSM vs. JAZZ, TEVA, GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, and QGEN

Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), and Qiagen (QGEN). These companies are all part of the "medical" sector.

Axsome Therapeutics vs. Its Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-49.88% -283.22% -33.06%
Jazz Pharmaceuticals -9.91%5.02%1.73%

In the previous week, Axsome Therapeutics had 9 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 18 mentions for Axsome Therapeutics and 9 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.00 beat Jazz Pharmaceuticals' score of 0.98 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jazz Pharmaceuticals
8 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Axsome Therapeutics currently has a consensus target price of $177.93, suggesting a potential upside of 39.08%. Jazz Pharmaceuticals has a consensus target price of $178.93, suggesting a potential upside of 31.51%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.00
Jazz Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$495.03M12.90-$287.22M-$5.07-25.23
Jazz Pharmaceuticals$4.07B2.03$560.12M-$6.73-20.22

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXSM vs. The Competition

MetricAxsome TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.38B$3.44B$6.21B$10.54B
Dividend YieldN/A2.28%5.70%4.80%
P/E Ratio-25.2323.1685.7027.13
Price / Sales12.90449.16581.70177.21
Price / CashN/A46.9237.1060.81
Price / Book108.4210.4112.236.52
Net Income-$287.22M-$52.77M$3.33B$276.93M
7 Day Performance5.12%2.31%1.17%1.93%
1 Month Performance10.34%12.59%6.85%2.19%
1 Year Performance37.05%11.18%58.93%34.62%

Axsome Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXSM
Axsome Therapeutics
4.7333 of 5 stars
$127.94
+2.4%
$177.93
+39.1%
+37.1%$6.38B$495.03M-25.23380Positive News
Analyst Revision
JAZZ
Jazz Pharmaceuticals
4.5661 of 5 stars
$135.14
-0.2%
$178.93
+32.4%
+18.3%$8.20B$4.07B-20.082,800
TEVA
Teva Pharmaceutical Industries
3.5875 of 5 stars
$20.02
-0.1%
$25.57
+27.8%
+7.7%$22.96B$16.63B-125.0936,830
GMAB
Genmab A/S
3.6417 of 5 stars
$32.68
+2.7%
$40.80
+24.8%
+44.3%$20.98B$3.26B16.422,682Trending News
Analyst Forecast
Short Interest ↑
Analyst Revision
SMMT
Summit Therapeutics
3.006 of 5 stars
$22.93
+7.4%
$31.29
+36.4%
-1.0%$17.03B$700K-22.70110News Coverage
Upcoming Earnings
Gap Down
ASND
Ascendis Pharma A/S
2.836 of 5 stars
$208.43
-0.5%
$248.29
+19.1%
+62.0%$12.86B$393.54M-40.391,017News Coverage
Analyst Upgrade
Analyst Revision
RDY
Dr. Reddy's Laboratories
3.0671 of 5 stars
$14.36
+0.1%
$16.95
+18.1%
-9.4%$11.99B$3.81B21.7527,811Positive News
VTRS
Viatris
3.0567 of 5 stars
$9.86
+1.2%
$10.40
+5.5%
-13.5%$11.50B$14.12B-3.4032,000News Coverage
Analyst Forecast
ROIV
Roivant Sciences
2.9516 of 5 stars
$16.21
+1.1%
$19.94
+23.0%
+44.8%$11.07B$29.05M-23.16860Insider Trade
BBIO
BridgeBio Pharma
4.4987 of 5 stars
$55.96
+0.8%
$63.94
+14.3%
+111.1%$10.70B$235.81M-13.68400Positive News
Analyst Revision
QGEN
Qiagen
4.136 of 5 stars
$47.30
+1.0%
$49.40
+4.4%
+15.5%$10.51B$2.04B27.955,765News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:AXSM) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners